Periodic Reporting for period 1 - in silico bio-evolutio (in silico bio-evolutio - novel AI paradigm for molecular biology)
Período documentado: 2023-01-01 hasta 2023-12-31
In practice, this goal can be achieved by accelerating activities in laboratory conditions in vitro / in vivo and the directional process of scientific thought created around this vector. Our mission is to expand access to in-silico methodologies that address both of the above goals. At the same time, scientific thought is developing in the heads of individual scientists and their groups - this process is still not fast enough and could be significantly accelerated by stimulating collaboration between individual scientists and groups, and as a result the dynamic creation of both: new ad hoc and long-term research groups. This is the vision that guides us in the implementation of the project and which you have a chance to deliver both: a number of outcomes for various groups of patients, but also the scientific community in terms of the pace of development of molecular therapies and, at the same time, the integration of their efforts. It is also a way to create the effect of strengthening the natural intelligence of research groups through AI tools, which in such use would not replace laboratory staff but make it more effective. This is a vision for sustainable co-evolution of technology with human capabilities, which will not be an addition to modern technologies, but will remain superior to this technology, at the same more friendly towards other scientists as co-contributors to distributed and shared intelligence, which is the future of humanity.
Camino Science is a cutting-edge biotechnology company that specializes in leveraging the power of artificial intelligence (AI) models to predict interactions between organisms. Our mission is to revolutionize the field of biotechnology by harnessing the vast potential of AI-driven systems for a deeper understanding of the complex relationships and interactions that shape the biological world.
At the same time, the generic methodology of building AI / ML models allowed us to scale both R&D processes and their production use in a mass application.
The developed mathematical and architectural solutions of AI / ML gave us the IP material that is the basis of international patent applications. At the same time, the existing solutions have aroused interest in the world of molecular biology science and allow for both scientific and commercial partnerships and the definition of a number of biotechnological usecases in emerging markets.
Main needs:
-Further in vitro studies confirming the predictive results of the AI engine.
-Ensuring broadband and international protection in the IP area.
-Demonstrating the achieved results to both the scientific and commercial environment (through publications and speeches in defined channels of reaching out, including scientific conferences and trade fairs).
-Access to our sources of financing both the investment world and public funds allowing for scalable access to international markets of selected biotechnology sectors.
-Cooperation with defined groups working on legislation related to emerging markets, including in particular the use of in-silico methods and standardization of their use.